Medication treatment of Kaposiform hemangioendothelioma and tufted angioma: a meta-analysis of proportions
10.3760/cma.j.cn114453-20200304-00107
- VernacularTitle:卡波西样血管内皮瘤及丛状血管瘤的药物治疗：单组率的meta分析
- Author:
Luying WANG
1
;
Shaohua LI
;
Xiaoyun YE
;
Renrong LYU
;
Guangqi XU
;
Jianhai BI
;
Ran HUO
Author Information
1. 山东大学附属省立医院整形美容外科，济南 250021
- Keywords:
Kaposiform hemangioendothelioma;
Tufted angioma;
Kasabach-Merritt phenomenon;
Vincristine;
Sirolimus;
Glucocorticoid.
- From:
Chinese Journal of Plastic Surgery
2020;36(4):375-384
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To assess the efficacy and safety of common medication treatments on Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA).Methods:PubMed, Embase, Web of Science, CNKI and Wanfang database were searched to find out the observational studies on medication treatment of KHE and TA. R-3.6.2 was used for calculate the pooled response rate and pooled adverse events rate. Meta analyses were performed according to KHE and TA with and without Kasabach-Merritt phenomenon (KMP) respectively. SPSS 22.0 was used to compare the pooled rates among each therapy.Results:A total of 30 studies regarding the medication treatment of KHE and TA were identified in this meta-analysis. Analyzed medicines included glucocorticoid, vincristine, sirolimus, propranolol, combination therapy of vincristine and glucocorticoid. The pooled results indicated that when referring therapy on KHE and TA with KMP, the pooled response rate of combination therapy (98.34%) and sirolimus (96.43%) was higher than that of other therapies, and the difference was statistically significant. The pooled adverse events rate of sirolimus (5.53%) was relatively higher than other modalities, with no statistically significance. As for therapy on KHE and TA without KMP, sirolimus (94.23%) had higher pooled response rate than glucocorticoid (31.25%), vincristine (46.15%) and propranolol (22.86%), with statistically significant differences. The pooled adverse events rate of sirolimus was 23.81%.Conclusions:Our findings indicate that for KHE and TA with KMP, combination therapy (sirolimus + glucocorticoid) and vincristine have the best efficacy, while the adverse events rate of sirolimus is relatively high. For KHE and TA without KMP, sirolimus has the highest response rate, but there is also a risk of serious adverse events. Glucocorticoid and vincristine have comparable response rate, which both inferior to sirolimus.
